tqb2928
Recombinant proteinexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2021 (NCT04854681)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06585059 | Phase 1 | Sep 30, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06297642 | Phase 1 | May 24, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06438783 | Phase 1 | Feb 15, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06008405 | Phase 1 | Sep 30, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05192512 | Phase 1 | Jan 24, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04854681 | Phase 1 | Aug 1, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 6 | 6 | 1 | 2021 |
1 organizations
Page 1 / 1